Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 105
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Am J Emerg Med ; 76: 217-224, 2024 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-38128162

RESUMEN

BACKGROUND: The COVID-19 pandemic has posed significant challenges to healthcare systems worldwide, including an increase in out-of-hospital cardiac arrests (OHCA). Healthcare providers are now required to use personal protective equipment (PPE) during cardiopulmonary resuscitation (CPR). Additionally, mechanical CPR devices have been introduced to reduce the number of personnel required for resuscitation. This study aimed to compare the outcomes of CPR performed with a mechanical device and the outcomes of manual CPR performed by personnel wearing PPE. METHODS: This multicenter observational study utilized data from the Korean Cardiac Arrest Research Consortium registry. The study population consisted of OHCA patients who underwent CPR in emergency departments (EDs) between March 2020 and June 2021. Patients were divided into two equal propensity score matched groups: mechanical CPR group (n = 421) and PPE-equipped manual CPR group (n = 421). Primary outcomes included survival rates and favorable neurological outcomes at discharge. Total CPR duration in the ED was also assessed. RESULTS: There were no significant between-group differences with respect to survival rate at discharge (mechanical CPR: 7.4% vs PPE-equipped manual CPR: 8.3%) or favorable neurological outcomes (3.3% vs. 3.8%, respectively). However, the mechanical CPR group had a longer duration of CPR in the ED compared to the manual CPR group. CONCLUSION: This study found no significant differences in survival rates and neurological outcomes between mechanical CPR and PPE-equipped manual CPR in the ED setting. However, a longer total CPR duration was observed in the mechanical CPR group. Further research is required to explore the impact of PPE on healthcare providers' performance and fatigue during CPR in the context of the pandemic and beyond.


Asunto(s)
COVID-19 , Reanimación Cardiopulmonar , Servicios Médicos de Urgencia , Paro Cardíaco Extrahospitalario , Humanos , Reanimación Cardiopulmonar/métodos , Pandemias , COVID-19/epidemiología , Paro Cardíaco Extrahospitalario/terapia
2.
Acta Pharmacol Sin ; 38(1): 90-99, 2017 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-27890918

RESUMEN

Mast cells are important effector cells in immunoglobulin (Ig) E-mediated allergic reactions such as asthma, atopic dermatitis and rhinitis. Vanillic acid, a natural product, has shown anti-oxidant and anti-inflammatory activities. In the present study, we investigated the anti-allergic inflammatory effects of ortho-vanillic acid (2-hydroxy-3-methoxybenzoic acid, o-VA) that was a derivative of vanillic acid isolated from Amomum xanthioides. In mouse anaphylaxis models, oral administration of o-VA (2, 10, 50 mg/kg) dose-dependently attenuated ovalbumin-induced active systemic anaphylaxis and IgE-mediated cutaneous allergic reactions such as hypothermia, histamine release, IgE production and vasodilation; administration of o-VA also suppressed the mast cell degranulator compound 48/80-induced anaphylaxis. In cultured mast cell line RBL-2H3 and isolated rat peritoneal mast cells in vitro, pretreatment with o-VA (1-100 µmol/L) dose-dependently inhibited DNP-HSA-induced degranulation of mast cells by decreasing the intracellular free calcium level, and suppressed the expression of pro-inflammatory cytokines TNF-α and IL-4. Pretreatment of RBL-2H3 cells with o-VA suppressed DNP-HSA-induced phosphorylation of Lyn, Syk, Akt, and the nuclear translocation of nuclear factor-κB. In conclusion, o-VA suppresses the mast cell-mediated allergic inflammatory response by blocking the signaling pathways downstream of high affinity IgE receptor (FcεRI) on the surface of mast cells.


Asunto(s)
Anafilaxia/tratamiento farmacológico , Anafilaxia/inmunología , Benzoatos/farmacología , Benzoatos/uso terapéutico , Hipersensibilidad/tratamiento farmacológico , Mastocitos/efectos de los fármacos , Receptores de IgE/inmunología , Ácido Vanílico/análogos & derivados , Anafilaxia/inducido químicamente , Animales , Calcio/metabolismo , Degranulación de la Célula/efectos de los fármacos , Células Cultivadas , Dinitrofenoles/antagonistas & inhibidores , Relación Dosis-Respuesta a Droga , Hipersensibilidad/inmunología , Inmunoglobulina E/efectos de los fármacos , Mediadores de Inflamación/metabolismo , Masculino , Mastocitos/inmunología , Ratones , FN-kappa B/metabolismo , Ovalbúmina/antagonistas & inhibidores , Fosforilación/efectos de los fármacos , Ratas , Receptores de IgE/antagonistas & inhibidores , Albúmina Sérica/antagonistas & inhibidores , Transducción de Señal/efectos de los fármacos , p-Metoxi-N-metilfenetilamina/antagonistas & inhibidores
3.
J Appl Toxicol ; 37(5): 554-562, 2017 05.
Artículo en Inglés | MEDLINE | ID: mdl-27682001

RESUMEN

Perfluorooctanoic acid (PFOA) has wide applications, including as a raw material for converted paper and packaging products. With the widespread use of PFOA, concerns regarding its potential environmental and health impacts have increased. In spite of the known hepatotoxicity and genotoxicity of PFOA, correlation with PFOA and allergic inflammation is not well known. In this study, the effect of PFOA on the degranulation of mast cells and mast cell-mediated allergic inflammation in the presence of FcεRI cross-linking was evaluated. In immunoglobulin (Ig) E-stimulated mast cells, PFOA increased the release of histamine and ß-hexosaminidase by the up-regulation of intracellular calcium levels. PFOA enhanced gene expression of several pro-inflammatory cytokines, including tumor necrosis factor (TNF)-α, interleukin (IL)-1ß, IL-6, and IL-8 by the activation of nuclear factor (NF)-κB in IgE-stimulated mast cells. Also, PFOA exacerbated allergic symptoms via hypothermia, and an increase of serum histamine, TNF-α, IgE and IgG1 in the ovalbumin-induced systemic anaphylaxis. The present data indicate that PFOA aggravated FcɛRI-mediated mast cell degranulation and allergic symptoms. Copyright © 2016 John Wiley & Sons, Ltd.


Asunto(s)
Caprilatos/toxicidad , Degranulación de la Célula/efectos de los fármacos , Fluorocarburos/toxicidad , Hipersensibilidad/patología , Inflamación/patología , Mastocitos/efectos de los fármacos , Anafilaxia/inducido químicamente , Anafilaxia/patología , Animales , Calcio/metabolismo , Supervivencia Celular/efectos de los fármacos , Citocinas/biosíntesis , Liberación de Histamina/efectos de los fármacos , Inmunoglobulina E/inmunología , Fragmentos Fc de Inmunoglobulinas/metabolismo , Masculino , Mastocitos/patología , Ratones , Ratones Endogámicos ICR , beta-N-Acetilhexosaminidasas/metabolismo
4.
Molecules ; 22(6)2017 May 29.
Artículo en Inglés | MEDLINE | ID: mdl-28555061

RESUMEN

Gallic acid (3,4,5-trihydroxybenzoic acid), is a natural product found in various foods and herbs that are well known as powerful antioxidants. Our previous report demonstrated that it inhibits mast cell-derived inflammatory allergic reactions by blocking histamine release and pro-inflammatory cytokine expression. In this report, various amide analogs of gallic acid have been synthesized by introducing different amines through carbodiimide-mediated amide coupling and Pd/C-catalyzed hydrogenation. These compounds showed a modest to high inhibitory effect on histamine release and pro-inflammatory cytokine expression. Among them, the amide bearing (S)-phenylglycine methyl ester 3d was found to be more active than natural gallic acid. Further optimization yielded several (S)- and (R)-phenylglycine analogs that inhibited histamine release in vitro. Our findings suggest that some gallamides could be used as a treatment for allergic inflammatory diseases.


Asunto(s)
Ácido Gálico/análogos & derivados , Ácido Gálico/química , Antagonistas de los Receptores Histamínicos/síntesis química , Antagonistas de los Receptores Histamínicos/uso terapéutico , Inflamación/tratamiento farmacológico , Mastocitos/inmunología , Animales , Antagonistas de los Receptores Histamínicos/química , Humanos , Hipersensibilidad/tratamiento farmacológico
5.
Pharm Biol ; 55(1): 1946-1953, 2017 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-28724321

RESUMEN

CONTEXT: Diospyros kaki L. (Ebenaceae) fruit is widely distributed in Asia and is known to exert anti-inflammatory and antithrombotic effects. OBJECTIVE: We evaluated the inhibitory effect of aqueous extract of D. kaki calyx (AEDKC) on mast cell-mediated immediate-type hypersensitivity and underlying mechanism of action. MATERIALS AND METHODS: For in vivo, ovalbumin (OVA)-induced active systemic anaphylaxis (ASA) and immunoglobulin (Ig) E-mediated passive cutaneous anaphylaxis (PCA) models were used. In the ASA, AEDKC (1-100 mg/kg) was orally administered 3 times during 14 days. In the PCA, AEDKC was orally treated 1 h before the antigen challenge. The control drug dexamethasone was used to compare the effectiveness of AEDKC. For in vitro, IgE-stimulated RBL-2H3 cells and primary cultured peritoneal mast cells were used to determine the role of AEDKC (0.01-1 mg/mL). RESULTS: Oral administration of AEDKC dose dependently suppressed rectal temperature decrease and increases in serum histamine, total IgE, OVA-specific IgE, and interleukin (IL)-4 in the ASA. In the PCA, AEDKC reduced Evans blue pigmentation. Compared to dexamethasone (10 mg/kg), AEDKC (100 mg/kg) showed similar inhibitory effects in vivo. AEDKC concentration dependently suppressed the release of histamine and ß-hexosaminidase through the reduction of intracellular calcium in mast cells. In addition, AEDKC decreased the expression and secretion of tumour necrosis factor-α and IL-4 by the reduction of nuclear factor-κB. The inhibitory potential of AEDKC (1 mg/mL) was similar with dexamethasone (10 µM) in vitro. CONCLUSIONS: We suggest that AEDKC may be a potential candidate for the treatment of mast cell-mediated allergic diseases.


Asunto(s)
Anafilaxia/metabolismo , Diospyros , Hipersensibilidad/metabolismo , Mastocitos/metabolismo , Extractos Vegetales/uso terapéutico , Anafilaxia/inducido químicamente , Anafilaxia/prevención & control , Animales , Supervivencia Celular/efectos de los fármacos , Supervivencia Celular/fisiología , Células Cultivadas , Relación Dosis-Respuesta a Droga , Hipersensibilidad/prevención & control , Masculino , Mastocitos/efectos de los fármacos , Ratones , Ratones Endogámicos ICR , Ovalbúmina/inmunología , Ovalbúmina/toxicidad , Extractos Vegetales/aislamiento & purificación , Extractos Vegetales/farmacología , Ratas , Ratas Sprague-Dawley
6.
Toxicol Appl Pharmacol ; 290: 1-9, 2016 Jan 01.
Artículo en Inglés | MEDLINE | ID: mdl-26570984

RESUMEN

Rheumatoid arthritis (RA) is a chronic autoimmune disease associated with a combination of synovium joint inflammation, synovium hyperplasia, and destruction of cartilage and bone. Oleanolic acid acetate (OAA), a compound isolated from Vigna angularis, has been known to possess pharmacological activities, including anti-inflammation and anti-bone destruction. In this study, we investigated the effects of OAA on RA and the underlying mechanisms of action by using a type-II collagen-induced arthritis (CIA) mouse model and tumor necrosis factor (TNF)-α-stimulated RA synovial fibroblasts. Oral administration of OAA decreased the clinical arthritis symptoms, paw thickness, histologic and radiologic changes, and serum total and anti-type II collagen IgG, IgG1, and IgG2a levels. OAA administration reduced Th1/Th17 phenotype CD4(+) T lymphocyte expansions and inflammatory cytokine productions in T cell activated draining lymph nodes and spleen. OAA reduced the expression and production of inflammatory mediators, such as cytokines and matrix metalloproteinase (MMP)-1/3, in the ankle joint tissue and RA synovial fibroblasts by down-regulating Akt, mitogen-activated protein kinases, and nuclear factor-κB. Our results clearly support that OAA plays a therapeutic role in RA pathogenesis by modulating helper T cell immune responses and matrix-degrading enzymes. The immunosuppressive effects of OAA were comparable to dexamethasone and ketoprofen. We provide evidences that OAA could be a potential therapeutic candidate for RA.


Asunto(s)
Artritis Reumatoide/tratamiento farmacológico , Linfocitos T/inmunología , Triterpenos/farmacología , Adulto , Animales , Artritis Experimental/tratamiento farmacológico , Huesos/efectos de los fármacos , Huesos/metabolismo , Cartílago/efectos de los fármacos , Cartílago/metabolismo , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Dexametasona/farmacología , Modelos Animales de Enfermedad , Regulación hacia Abajo , Fibroblastos/efectos de los fármacos , Fibroblastos/metabolismo , Humanos , Inmunoglobulina G/sangre , Cetoprofeno/farmacología , Masculino , Metaloproteinasa 13 de la Matriz/genética , Metaloproteinasa 13 de la Matriz/metabolismo , Metaloproteinasa 3 de la Matriz/genética , Metaloproteinasa 3 de la Matriz/metabolismo , Ratones , Ratones Endogámicos DBA , Persona de Mediana Edad , Proteínas Quinasas Activadas por Mitógenos/genética , Proteínas Quinasas Activadas por Mitógenos/metabolismo , FN-kappa B/genética , FN-kappa B/metabolismo , Membrana Sinovial/efectos de los fármacos , Membrana Sinovial/metabolismo , Linfocitos T/citología , Factor de Necrosis Tumoral alfa/farmacología
7.
Toxicol Appl Pharmacol ; 287(2): 119-127, 2015 Sep 01.
Artículo en Inglés | MEDLINE | ID: mdl-25981167

RESUMEN

As the importance of allergic disorders such as atopic dermatitis and allergic asthma, research on potential drug candidates becomes more necessary. Mast cells play an important role as initiators of allergic responses through the release of histamine; therefore, they should be the target of pharmaceutical development for the management of allergic inflammation. In our previous study, anti-allergic effect of extracts of Amomum xanthioides was demonstrated. To further investigate improved candidates, 1,2,4,5-tetramethoxybenzene (TMB) was isolated from methanol extracts of A. xanthioides. TMB dose-dependently attenuated the degranulation of mast cells without cytotoxicity by inhibiting calcium influx. TMB decreased the expression of pro-inflammatory cytokines such as tumor necrosis factor-α and interleukin (IL)-4 at both the transcriptional and translational levels. Increased expression of these cytokines was caused by translocation of nuclear factor-κB into the nucleus, and it was hindered by suppressing activation of IκB kinase complex. To confirm the effect of TMB in vivo, the ovalbumin (OVA)-induced active systemic anaphylaxis (ASA) and IgE-mediated passive cutaneous anaphylaxis (PCA) models were used. In the ASA model, hypothermia was decreased by oral administration of TMB, which attenuated serum histamine, OVA-specific IgE, and IL-4 levels. Increased pigmentation of Evans blue was reduced by TMB in a dose-dependent manner in the PCA model. Our results suggest that TMB is a possible therapeutic candidate for allergic inflammatory diseases that acts through the inhibition of mast cell degranulation and expression of pro-inflammatory cytokines.


Asunto(s)
Anisoles/farmacología , Inflamación/tratamiento farmacológico , Inflamación/fisiopatología , Amomum , Animales , Degranulación de la Célula/efectos de los fármacos , Citocinas/antagonistas & inhibidores , Relación Dosis-Respuesta a Droga , Hipersensibilidad , Quinasa I-kappa B/biosíntesis , Mediadores de Inflamación/antagonistas & inhibidores , Masculino , Mastocitos/efectos de los fármacos , Ratones , Extractos Vegetales/farmacología , Ratas , Ratas Sprague-Dawley
8.
Toxicol Appl Pharmacol ; 274(3): 455-61, 2014 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-24361550

RESUMEN

A great number of people are suffering from allergic inflammatory disease such as asthma, atopic dermatitis, and sinusitis. Therefore discovery of drugs for the treatment of these diseases is an important subject in human health. Putranjivain A (PJA), member of ellagitannin, is known to possess beneficial effects including anti-cancer and anti-viral activities. The aim of the present study was to elucidate whether PJA modulates the allergic inflammatory reaction and to study its possible mechanisms of action using mast cell-based in vitro and in vivo models. The study was performed in anaphylaxis mouse model and cultured mast cells. PJA inhibited the expression of pro-inflammatory cytokines in immunoglobulin E-stimulated mast cells. PJA reduced this expression by inhibiting nuclear factor (NF)-κB and nuclear factor of activated T cell. The oral administration of PJA reduced systemic and cutaneous anaphylaxis, the release of serum histamine, and the expression of the histamine H1 receptor. In addition, PJA attenuated the activation of mast cells. PJA inhibited the release of histamine from various types of mast cells by the suppression of intracellular calcium. The inhibitory activity of PJA on the allergic reaction was similar to that of disodium cromoglycate, a known anti-allergic drug. These results suggest that PJA can facilitate the prevention or treatment of allergic inflammatory diseases mediated by mast cells.


Asunto(s)
Ácido Gálico/análogos & derivados , Glucósidos/farmacología , Inflamación/prevención & control , Mastocitos/efectos de los fármacos , Administración Oral , Animales , Antiasmáticos/farmacología , Células Cultivadas , Cromolin Sódico/farmacología , Citocinas/antagonistas & inhibidores , Citocinas/metabolismo , Ácido Gálico/farmacología , Liberación de Histamina/efectos de los fármacos , Humanos , Hipersensibilidad/tratamiento farmacológico , Inmunoglobulina E/metabolismo , Inflamación/tratamiento farmacológico , Masculino , Mastocitos/metabolismo , Ratones , Ratones Endogámicos ICR , FN-kappa B/antagonistas & inhibidores , FN-kappa B/metabolismo , Ratas , Receptores Histamínicos H1/genética , Receptores Histamínicos H1/metabolismo
9.
Immunopharmacol Immunotoxicol ; 33(2): 271-8, 2011 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-20626232

RESUMEN

In this study, we investigated the effect of the Meoruh wine (MW), a Korean traditional wine made by the fruits of Vitis amurensis Rupr. (Vitaceae) on the mast cell-mediated allergic inflammation and studied the possible mechanism of action. Mast cell-mediated allergic disease is involved in many diseases such as anaphylaxis, rhinitis, asthma, and atopic dermatitis. MW inhibited compound 48/80-induced systemic anaphylaxis and serum histamine release in a dose-dependent manner in mice. MW decreased immunoglobulin E-mediated local allergic reactions, passive cutaneous anaphylaxis. MW dose-dependently reduced histamine release from human mast cells activated by phorbol 12-myristate 13-acetate and calcium ionophore A23187 (PMACI). The inhibitory effect of MW on histamine release was mediated by suppression of intracellular calcium. In addition, MW attenuated the PMACI-stimulated expression of pro-inflammatory cytokines such as tumor necrosis factor-α, interleukin-1ß (IL-1ß), IL-6, and IL-8 in human mast cells. The inhibitory effect of MW on these pro-inflammatory cytokines was nuclear factor (NF)-κB dependent. Our findings provide evidence that MW inhibits mast cell-derived allergic inflammatory reactions and involvement of calcium, pro-inflammatory cytokines and NF-κB in these effects.


Asunto(s)
Mediadores de Inflamación/fisiología , Mastocitos/inmunología , Anafilaxis Cutánea Pasiva/inmunología , Vino , Animales , Línea Celular , Liberación de Histamina/inmunología , Humanos , Inflamación/inmunología , Inflamación/patología , Inflamación/prevención & control , Mediadores de Inflamación/antagonistas & inhibidores , Masculino , Mastocitos/patología , Ratones , Ratones Endogámicos ICR
10.
Materials (Basel) ; 13(17)2020 Sep 02.
Artículo en Inglés | MEDLINE | ID: mdl-32887467

RESUMEN

Curing by CO2 is a way to utilize CO2 to reduce greenhouse gas emissions. Placing early-age cement paste in a CO2 chamber or pressure vessel accelerates its strength development. Cement carbonation is attributed to the quickened strength development, and CO2 uptake can be quantitatively evaluated by measuring CO2 gas pressure loss in the pressure vessel. A decrease in CO2 gas pressure is observed with all cement pastes and mortar samples regardless of the mix proportion and the casting method; one method involves compacting a low water-to-cement ratio mix, and the other method comprises a normal mix consolidated in a mold. The efficiency of the CO2 curing is superior when a 20% concentration of CO2 gas is supplied at a relative humidity of 75%. CO2 uptake in specimens with the same CO2 curing condition is different for each specimen size. As the specimen scale is larger, the depth of carbonation is smaller. Incorporating colloidal silica enhances the carbonation as well as the hydration of cement, which results in contributing to the increase in the 28-day strength.

11.
Materials (Basel) ; 13(11)2020 May 27.
Artículo en Inglés | MEDLINE | ID: mdl-32471169

RESUMEN

This paper reports the electrical resistivity measurements on KOH-activated ground-granulated blast-furnace slag, which was mixed with deionized water or natural seawater at three different activator-to-binder ratios (0.4, 0.45, and 0.5). Compressive strength and X-ray diffraction analyses were performed on the samples after the measurement. The type of mixing water did not affect the setting time of samples, whereas the setting time was delayed with an increase in activator-to-binder (a/b) ratio. Regardless of the mixing water type, the increasing ratio of electrical resistivity between a/b 0.45 and 0.5 was larger than that between a/b 0.4 and 0.45. For the same a/b ratio, the pastes mixed with seawater produced higher electrical resistivity and early strength than those with deionized water. The increase in the electrical resistivity in seawater-mixed pastes could be attributed to the formation of Cl-bearing phases such as Cl-hydrocalumite, AlOCl, and aluminum chloride hydrate. It is believed that the reaction products in seawater-mixed samples were helpful in preventing water percolation, and thus, the electrical resistivity increased compared with the deionized water-mixed sample.

12.
J Ethnopharmacol ; 250: 112484, 2020 Mar 25.
Artículo en Inglés | MEDLINE | ID: mdl-31843576

RESUMEN

ETHNOPHARMACOLOGICAL RELEVANCE: A promising approach to treat a variety of diseases are considered as complementary and alternative herbal medicines. Prunus serrulata var. spontanea L. (Rosaceae) is used as herbal medicine to treat allergic diseases according to the Donguibogam, a tradition medical book of the Joseon Dynasty in Korea. AIM OF THE STUDY: We prepared the aqueous extract of the bark of P. serrulata (AEBPS) and aimed to investigate the effects in mouse anaphylaxis models and various types of mast cells, including RBL-2H3, primary cultured peritoneal and bone marrow-derived mast cells. MATERIALS AND METHODS: We used ovalbumin (OVA)-induced active systemic anaphylaxis (ASA) and immunoglobulin (Ig) E-mediated passive cutaneous anaphylaxis (PCA) models, in vivo. The control drug dexamethasone (10 mg/kg) was used to compare the effectiveness of AEBPS (1-100 mg/kg). In vitro, IgE-stimulated mast cells were used to confirm the role of AEBPS (1-100 µg/mL). For statistical analyses, p values less than 0.05 were considered to be significant. RESULTS: In ASA model, oral administration of AEBPS suppressed the hypothermia and increased level of serum histamine in a dose-dependent manner. AEBPS attenuated the serum IgE, OVA-specific IgE, and interleukin (IL)-4. Oral administration of AEBPS also blocked mast cell-dependent PCA. AEBPS suppressed degranulation of mast cells by reducing intracellular calcium level in mast cells. AEBPS inhibited tumor necrosis factor-α and IL-4 expression and secretion in a concentration-dependent manner through the reduction of nuclear factor-κB. CONCLUSIONS: On the basis of these findings, AEBPS could serve as a potential therapeutic target for the management of mast cell-mediated allergic inflammation and as a regulator of mast cell activation.


Asunto(s)
Anafilaxia/tratamiento farmacológico , Mastocitos/inmunología , Extractos Vegetales/farmacología , Prunus/química , Anafilaxia/inmunología , Animales , Relación Dosis-Respuesta a Droga , Histamina/sangre , Inmunoglobulina E/inmunología , Masculino , Medicina Tradicional Coreana , Ratones , Ratones Endogámicos ICR , Ovalbúmina/inmunología , Anafilaxis Cutánea Pasiva/efectos de los fármacos , Anafilaxis Cutánea Pasiva/inmunología , Corteza de la Planta , Extractos Vegetales/administración & dosificación , Ratas , Ratas Sprague-Dawley
13.
Biomed Pharmacother ; 122: 109743, 2020 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-31918284

RESUMEN

Polyozellus multiplex is an edible mushroom that offers beneficial pharmacological effects against intestinal inflammation and cancer. Previous studies have demonstrated that polyozellin, a major component of P. multiplex, has therapeutic activities against inflammation, cancer, and oxidative stress-related disorders. This study aimed to determine the pharmacological effects of polyozellin on inflammatory and pruritic responses, the major symptoms of atopic dermatitis (AD), and to define its underlying mechanism of action. Our results showed that polyozellin inhibited the expression of inflammatory cytokines and chemokines through blockade of signal transducer and activator of transcription 1 and nuclear factor-κB in activated keratinocytes, the major cells involved in AD progression. Based on the histological and immunological analyses, oral treatment with polyozellin attenuated the Dermatophagoides farinae extract (DFE)/2,4-dinitrochlorobenzene (DNCB)-induced atopic inflammatory symptoms in the skin. Pruritus is an unpleasant sensation for AD patients that causes scratching behavior and ultimately exacerbates the severity of AD. To find a possible explanation for the anti-pruritic effects of polyozellin, we investigated its effects on mast cells and mast cell-derived histamines. Oral treatment with polyozellin reduced the DFE/DNCB-induced tissue infiltration of mast cells, the serum histamine levels, and the histaminergic scratching behaviors. Additionally, polyozellin decreased the immunoglobulin E-stimulated degranulation of mast cells. Taken together, the findings of this study provide us with novel insights into the potential pharmacological targets of polyozellin for treating AD by inhibiting the inflammatory and pruritic responses.


Asunto(s)
Dermatitis Atópica/tratamiento farmacológico , Furanos/farmacología , Inflamación/tratamiento farmacológico , Queratinocitos/efectos de los fármacos , Mastocitos/efectos de los fármacos , Animales , Línea Celular , Citocinas/metabolismo , Dermatitis Atópica/metabolismo , Dinitroclorobenceno/farmacología , Femenino , Histamina/metabolismo , Humanos , Inmunoglobulina E/metabolismo , Inflamación/metabolismo , Queratinocitos/metabolismo , Mastocitos/metabolismo , Ratones , Ratones Endogámicos BALB C , FN-kappa B/metabolismo , Piel/efectos de los fármacos , Piel/metabolismo , Factor de Necrosis Tumoral alfa/metabolismo
14.
Immunopharmacol Immunotoxicol ; 31(2): 314-9, 2009 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-19514997

RESUMEN

Leaves of Eriobotrya japonica Lindl. (Rosaceae) (LEJL) have been used as traditional medicines for inflammatory diseases and chronic bronchitis. However, its effect on mast cell-mediated anaphylactic reaction is not known. The anaphylactic allergic reaction is involved in many allergic diseases such as asthma and allergic rhinitis. In this report, we investigate the effect of LEJL on the anaphylactic allergic reaction and studied its possible mechanisms of action. LEJL inhibited compound 48/80-induced systemic anaphylactic reactions and serum histamine release in mice. LEJL dose-dependently decreased the IgE-mediated passive cutaneous anaphylaxis and histamine release from mast cells. Furthermore, LEJL decreased the production of tumor necrosis factor-alpha in phorbol 12-myristate 13-acetate and A23187-stimulated human mast cells. These findings provide evidence that LEJL could be a candidate as an anti-allergic agent.


Asunto(s)
Anafilaxia/terapia , Antialérgicos/inmunología , Eriobotrya/inmunología , Liberación de Histamina/inmunología , Factor de Necrosis Tumoral alfa/biosíntesis , Animales , Calcimicina/farmacología , Histamina/sangre , Histamina/inmunología , Humanos , Inmunoglobulina E/sangre , Inmunoglobulina E/inmunología , Masculino , Mastocitos/efectos de los fármacos , Ratones , Ratones Endogámicos ICR , Hojas de la Planta/inmunología , Ratas , Ratas Sprague-Dawley , Acetato de Tetradecanoilforbol/farmacología , p-Metoxi-N-metilfenetilamina/inmunología
15.
Immunopharmacol Immunotoxicol ; 31(2): 209-13, 2009 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-19514995

RESUMEN

Motherwort (MW), a Korean folk medicine, has been applied to treat inflammatory disease. However, its effect on inflammatory cytokine release from mast cells is not well known. We investigated the anti- inflammatory effect of MW on the secretion of inflammatory cytokine such as tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 and IL-8 in human mast cell line (HMC-1). MW was treated in vitro before activation of HMC-1 cells with phorbol 12-myristate 13-acetate (PMA) plus calcium ionophore A23187. MW had no cytotoxic effects on HMC-1 cell viability. MW (1 mg/ml) inhibited PMA plus A23187-stimulated gene expression and production of TNF-alpha, IL-6, and IL-8. Stimulation with PMA plus A23187 induced NF-kappaB activation in HMC-1 cells, which was inhibited by MW (1 mg/ml). MW inhibited secretion of TNF-alpha, IL-6, and IL-8 possibly by inhibiting NF-kappaB activation. These results indicate that MW may be helpful in regulating inflammatory diseases.


Asunto(s)
Antiinflamatorios/farmacología , Leonurus/metabolismo , Mastocitos/efectos de los fármacos , Extractos Vegetales/farmacología , Antiinflamatorios/metabolismo , Calcimicina/farmacología , Humanos , Inflamación/tratamiento farmacológico , Interleucina-6/metabolismo , Interleucina-8/metabolismo , Mastocitos/inmunología , Medicina Tradicional , FN-kappa B/metabolismo , Fitoterapia , Extractos Vegetales/metabolismo , Acetato de Tetradecanoilforbol/farmacología , Factor de Necrosis Tumoral alfa/metabolismo
16.
Materials (Basel) ; 12(21)2019 Oct 26.
Artículo en Inglés | MEDLINE | ID: mdl-31717738

RESUMEN

The effect of CO2 curing on alkali-activated slag paste activated by a mixture of sodium hydroxide and sodium silicate solutions is reported in this paper. The paste samples after demolding were cured in three different curing environments as follows: (1) environmental chamber maintained at 85% relative humidity (RH) and 25 °C; (2) 3-bar CO2 pressure vessel; and (3) CO2 chamber maintained at 20% CO2 concentration, 70% RH and 25 °C. The hardened samples were then subjected to compressive strength measurement, X-ray diffraction analysis, and thermogravimetry. All curing conditions used in this study were beneficial for the strength development of the alkali-activated slag paste samples. Among the curing environments, the 20% CO2 chamber was the most effective on compressive strength development; this is attributed to the simultaneous supply of moisture and CO2 within the chamber. The results of X-ray diffraction and thermogravimetry show that the alkali-activated slag cured in the 20% CO2 chamber received a higher amount of calcium silicate hydrate (C-S-H), while calcite formed at an early age was consumed with time. C-S-H was formed by associating the calcite generated by CO2 curing with the silica gel dissolved from alkali-activated slag.

17.
Chem Biol Interact ; 298: 1-7, 2019 Jan 25.
Artículo en Inglés | MEDLINE | ID: mdl-30392763

RESUMEN

Mast cells play a major role in immunoglobulin E-mediated allergic inflammation, which is involved in asthma, atopic dermatitis, and allergic rhinitis. Nothofagin has been shown to ameliorate various inflammatory responses such as the septic response and vascular inflammation. In this study, we assessed the inhibitory effect of nothofagin on allergic inflammation using cultured/isolated mast cells and an anaphylaxis mouse model. Nothofagin treatment prevented histamine and ß-hexosaminidase release by reducing the influx of calcium into the cytosol in a concentration-dependent manner. Nothofagin also inhibited the gene expression and secretion of pro-inflammatory cytokines such as tumor necrosis factor-α and interleukin-4 by downregulating the phosphorylation of Lyn, Syk, Akt and nuclear translocation of nuclear factor-κB. To confirm these effects of nothofagin in vivo, we used a passive cutaneous anaphylaxis mouse model. Topical administration of nothofagin suppressed local pigmentation and ear thickness. Taken together, these results suggest nothofagin as a potential candidate for the treatment of mast cell-involved allergic inflammatory diseases.


Asunto(s)
Chalconas/farmacología , Hipersensibilidad/tratamiento farmacológico , Inflamación/prevención & control , Mastocitos/efectos de los fármacos , Anafilaxia/etiología , Anafilaxia/prevención & control , Animales , Calcio/metabolismo , Degranulación de la Célula/efectos de los fármacos , Citocinas/genética , Citocinas/metabolismo , Modelos Animales de Enfermedad , Regulación de la Expresión Génica/efectos de los fármacos , Hipersensibilidad/complicaciones , Hipersensibilidad/patología , Inflamación/etiología , Inflamación/patología , Masculino , Mastocitos/fisiología , Ratones Endogámicos ICR , FN-kappa B/antagonistas & inhibidores , FN-kappa B/metabolismo , Ratas Sprague-Dawley
18.
J Ethnopharmacol ; 238: 111850, 2019 Jun 28.
Artículo en Inglés | MEDLINE | ID: mdl-30953820

RESUMEN

ETHNOPHARMACOLOGICAL RELEVANCE: Extracts from various parts of Ampelopsis brevipedunculata has been used as anti-inflammatory agents in Asian folk medicine. AIM OF THE STUDY: To demonstrate the medicinal effect of the A. brevipedunculata in skin inflammation, specifically atopic dermatitis (AD). MATERIALS AND METHODS: The effect of ethanol extract of A. brevipedunculata rhizomes (ABE) on AD was examined using an AD-like skin inflammation model induced by repeated exposure to house dust mite (Dermatophagoides farinae extract, DFE) and 2,4-dinitrochlorobenzene (DNCB). The mechanism study was performed using tumor necrosis factor (TNF)-α and interferon (IFN)-γ-activated human keratinocytes (HaCaT). Serum histamine and immunoglobulin levels were quantified using enzymatic kits, while the gene expression of cytokines and chemokines was analyzed using quantitative real time polymerase chain reaction. The expression of signaling molecules was detected using Western blot. RESULTS: Oral administration of ABE alleviated DFE/DNCB-induced ear thickening and clinical symptoms, as well as immune cell infiltration (mast cells and eosinophils) into the dermal layer. Serum Immunoglobulin (Ig) E, DFE-specific IgE, IgG2a, and histamine levels were decreased after the administration of ABE. ABE also inhibited CD4+IFN-γ+ and CD4+IL-4+ lymphocyte polarization in lymph nodes and expression of TNF-α, IFN-γ, IL-4, IL-13, and IL-31 in the ear tissue. In TNF-α/INF-γ-stimulated keratinocytes, ABE inhibited the gene expression of TNF-α, IL-6, IL-1ß, and CCL17. In addition, ABE decreased the nuclear localization of signal transducer and activator of transcription 1 and nuclear factor-κB, and the phosphorylation of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase. CONCLUSION: Collectively, our data demonstrate the pharmacological role and signaling mechanism of ABE in the regulation of skin allergic inflammation, which supports our suggestion that ABE could be developed as a potential therapeutic agent for the treatment of AD.


Asunto(s)
Ampelopsis , Antiinflamatorios/uso terapéutico , Dermatitis Atópica/tratamiento farmacológico , Extractos Vegetales/uso terapéutico , Animales , Antiinflamatorios/farmacología , Antígenos Dermatofagoides/inmunología , Línea Celular , Supervivencia Celular/efectos de los fármacos , Citocinas/inmunología , Dermatitis Atópica/sangre , Dermatitis Atópica/inmunología , Dermatitis Atópica/patología , Dinitroclorobenceno , Etanol/química , Femenino , Histamina/sangre , Humanos , Inmunoglobulina E/sangre , Queratinocitos/efectos de los fármacos , Ratones Endogámicos BALB C , Extractos Vegetales/farmacología , Rizoma , Piel/efectos de los fármacos , Piel/inmunología , Piel/patología , Solventes/química
19.
Front Pharmacol ; 10: 869, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31427975

RESUMEN

Mast cells are effector cells that induce allergic inflammation by secreting inflammatory mediators. Gomisin M2 (G.M2) is a lignan isolated from Schisandra chinensis (Turcz). Baill. exhibiting anti-cancer activities. We aimed to investigate the anti-allergic effects and the underlying mechanism of G.M2 in mast cell-mediated allergic inflammation. For the in vitro study, we used mouse bone marrow-derived mast cells, RBL-2H3, and rat peritoneal mast cells. G.M2 inhibited mast cell degranulation upon immunoglobulin E (IgE) stimulation by suppressing the intracellular calcium. In addition, G.M2 inhibited the secretion of pro-inflammatory cytokines. These inhibitory effects were dependent on the suppression of FcεRI-mediated activation of signaling molecules. To confirm the anti-allergic effects of G.M2 in vivo, IgE-mediated passive cutaneous anaphylaxis (PCA) and ovalbumin-induced active systemic anaphylaxis (ASA) models were utilized. Oral administration of G.M2 suppressed the PCA reactions in a dose-dependent manner. In addition, G.M2 reduced the ASA reactions, including hypothermia, histamine, interleukin-4, and IgE production. In conclusion, G.M2 exhibits anti-allergic effects through suppression of the Lyn and Fyn pathways in mast cells. According to these findings, we suggest that G.M2 has potential as a therapeutic agent for the treatment of allergic inflammatory diseases via suppression of mast cell activation.

20.
Eur J Pharmacol ; 579(1-3): 58-65, 2008 Jan 28.
Artículo en Inglés | MEDLINE | ID: mdl-17980359

RESUMEN

Hypoxia-inducible factor-1 (HIF-1) is an important tumor-selective therapeutic target for solid tumors. Icariside II was isolated from Epimedium koreanum through successive fractionation with ethyl acetate, n-butanol, chloroform and hexane, followed by gel column chromatography. Icariside II attenuated the protein level of HIF-1alpha induced by hypoxia in human osteosarcoma (HOS) cells in a concentration-dependent manner, probably by enhancing the interaction rate between von Hippel-Lindau (VHL) and HIF-1alpha. Furthermore, Icariside II down-regulated the levels of HIF-inducible genes involved in angiogenesis, metastasis, and glucose metabolism, such as vascular endothelial growth factor (VEGF), urokinase plasminogen activator receptor (uPAR), adrenomedullin (ADM), matrix metalloproteinase 2 (MMP2), aldolase A, and enolase 1 in HOS cells. Icariside II also inhibited the migration rate in HOS cells and tube formation rate in human umbilical vein endothelium cells (HUVECs). Overall, these results suggest the potential use of Icariside II as a therapeutic candidate against various diseases that involve overexpression of HIF-1alpha.


Asunto(s)
Epimedium/química , Flavonoides/farmacología , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Subunidad alfa del Factor 1 Inducible por Hipoxia/efectos de los fármacos , Adrenomedulina/efectos de los fármacos , Adrenomedulina/genética , Neoplasias Óseas/metabolismo , Línea Celular Tumoral , Relación Dosis-Respuesta a Droga , Regulación hacia Abajo/efectos de los fármacos , Flavonoides/administración & dosificación , Fructosa-Bifosfato Aldolasa/efectos de los fármacos , Fructosa-Bifosfato Aldolasa/genética , Humanos , Subunidad alfa del Factor 1 Inducible por Hipoxia/genética , Subunidad alfa del Factor 1 Inducible por Hipoxia/metabolismo , Metaloproteinasa 2 de la Matriz/efectos de los fármacos , Metaloproteinasa 2 de la Matriz/genética , Osteosarcoma/metabolismo , Fosfopiruvato Hidratasa/efectos de los fármacos , Fosfopiruvato Hidratasa/genética , Receptores de Superficie Celular/efectos de los fármacos , Receptores de Superficie Celular/genética , Receptores del Activador de Plasminógeno Tipo Uroquinasa , Factor A de Crecimiento Endotelial Vascular/efectos de los fármacos , Factor A de Crecimiento Endotelial Vascular/genética , Proteína Supresora de Tumores del Síndrome de Von Hippel-Lindau/efectos de los fármacos , Proteína Supresora de Tumores del Síndrome de Von Hippel-Lindau/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA